Article
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Gastroenterology - 1 Jun 2009
Chan Andrew T, Zauber Ann G, Hsu Meier, Breazna Aurora, Hunter David J, Rosenstein Rebecca B, Eagle Craig J, Hawk Ernest T, Bertagnolli Monica M
Abstract excerpt
BACKGROUND & AIMS: Variants in the cytochrome P450 2C9 (CYP2C9) gene are associated with impaired metabolism of celecoxib. We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib. METHODS: We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
